HOME >> MEDICINE >> NEWS
Newer diabetic meds cost more, but users have fewer hospital visits

Diabetics who were prescribed newer medications to control their illness were more likely to take these drugs as instructed than were other patients who were prescribed drugs that have been on the market for several decades.

A new study suggests that patients on the newer medications had a slightly lower risk of hospitalization because of diabetes-related complications. They also spent between $920 and $1,760 less on annual total healthcare costs.

The researchers analyzed more than three years' worth of medical records' data on patients who took thiazolidinediones (TZDs) or either metformin or a sulfonylurea to control their diabetes. TZDs (pioglitazone and rosiglitazone, brand names Actos and Avandia, respectively), were approved by the Food and Drug Administration in the late 1990s. Metformin and sulfonylureas have been on the market for more than 50 years.

"Taking a TZD as instructed was the strongest predictor of a reduced risk of hospitalization and decreased healthcare costs in this group of patients," said Rajesh Balkrishnan, the study's lead author and the Merrell Dow professor of pharmacy at Ohio State University.

The issue is that TZDs can be 10 times more expensive than the older diabetes drugs, Balkrishnan said.

"There are a lot of new medications on the market for treating diabetes," Balkrishnan said. "Although some of these newer drugs are more expensive, that extra expense is made up for by a reduction of cost in other aspects of healthcare use."

The study appears in a recent issue of the journal Current Medical Research and Opinion.

The researchers collected information on 3,191 adults enrolled in the North Carolina Medicaid program, which covers all medical and prescription costs of its enrollees. All of the participants had Type 2 diabetes and started medications for the disease between July 2001 and December 2003.

The enrollees were divided into two groups based on the type of drug th
'"/>

Contact: Rajesh Balkrishnan
Balkrishnan.1@osu.edu
614-292-6415
Ohio State University
21-Mar-2006


Page: 1 2 3

Related medicine news :

1. Newer biomarkers add small improvement in cardiovascular risk prediction to established risk factors
2. Newer chemotherapies improve outcomes for some types of breast cancer
3. Newer form of cardiac imaging providing better look at heart
4. Newer imaging techniques may lead to over-treatment
5. Researchers find vitamin B1 deficiency key to vascular problems for diabetic patients
6. When it comes to preventing amputation in diabetics, site, not size, matters
7. Long-term anti-clotting therapy sweetens stenting outcomes in diabetic patients
8. UW study tests topical honey as a treatment for diabetic ulcers
9. Simple classification can help define and predict limb-threatening diabetic infections
10. Glucose levels trigger compensation for type 2 diabetics
11. Drug treatment slows macular vision loss in diabetics

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Newer diabetic meds cost more but users have fewer hospital visits

(Date:4/24/2015)... (PRWEB) April 24, 2015 The 1975 ... toured almost constantly across the globe to theaters, festivals and ... in Manchester, they’ve partnered with their label, Dirty Hit Records, ... Teaming up with the newly launched Cadence & Cause ... their debut LP on vinyl and a signed photo card. ...
(Date:4/24/2015)... April 24, 2015 Lowcostcarinsuranceprice.com has released ... low cost auto insurance for senior citizens . ... but this does not mean that they cannot find ... senior drivers can find the right coverage for their ... brokerage website like http://lowcostcarinsuranceprice.com/ provides free leads ...
(Date:4/24/2015)... Integrative Therapeutics has introduced two new supplements focused ... A unique combination of herbs and nutrients, including ... apart from other antioxidant supplements. This formula relies ... versus the use of single or sequential compounds ... Alpha-Glycosyl Isoquercitrin, and Coenzyme Q10 with Setria® Glutathione. ...
(Date:4/24/2015)... With years of experience providing consumer ... to be partnered with a veterinary college where veterinary ... This partnership has brought new payment options for families ... providing an in-house payment plan for many years, the ... to increase financing options available to avoid having to ...
(Date:4/24/2015)... 2015 IntelliSoft Group, LLC, a ... contract management software, featured IntelliCred Version 14.2 during ... Annual Educational Conference (IAMSS) on April 23-24 ... Brook, Illinois. , Notable improvements available in IntelliSoft’s ... , Contract Linking: A new Contract Connection ...
Breaking Medicine News(10 mins):Health News:Internationally Recognized British Indie Rock Outfit The 1975 Partner with Cadence & Cause to Provide Clean Drinking Water to Those in Need 2Health News:Low Cost Auto Insurance Quotes for Senior Citizens 2Health News:Integrative Therapeutics Introduces Two ProThrivers™ Wellness Supplements with Specialty Ingredients from Kyowa Hakko USA 2Health News:Integrative Therapeutics Introduces Two ProThrivers™ Wellness Supplements with Specialty Ingredients from Kyowa Hakko USA 3Health News:Integrative Therapeutics Introduces Two ProThrivers™ Wellness Supplements with Specialty Ingredients from Kyowa Hakko USA 4Health News:University of Missouri Veterinary Medical Teaching Hospital Teams with UGA 2Health News:IntelliSoft Group Version 14.2 of IntelliCred featured at the Illinois Association of Medical Staff Services Annual Educational Conference 2
(Date:4/24/2015)... 2015 Research and Markets ... of the "Lab Accessories Market by ... Station) & End User (OEM/Biotechnology & Pharmaceutical ... 2020" report to their offering. ... expected to reach $504.7 million by 2020 ...
(Date:4/24/2015)... Company, Inc. (NYSE: LCI ) today announced that ... facility to $120 million from $50 million.  The amended ... company to increase borrowings by a total of up ... commitments from existing lenders or new lending institutions.  The ... 2018.   "The amended credit facility, together ...
(Date:4/23/2015)... CHICAGO, Ill. , April 24, 2015  AbbVie ... Food and Drug Administration (FDA) has accepted its New ... company,s, all-oral, interferon-free, two direct-acting antiviral treatment of ombitasvir, ... for the treatment of adults with chronic genotype 4 ... regimen is the first all-oral, interferon-free therapy being evaluated ...
Breaking Medicine Technology:Global Lab Accessories Market Report 2015-2020 - Label Printer/ Pipette tips/ Pumps/Microplate/Reagent Reservoir/Valve/Tubing/Wash Station 2Global Lab Accessories Market Report 2015-2020 - Label Printer/ Pipette tips/ Pumps/Microplate/Reagent Reservoir/Valve/Tubing/Wash Station 3Lannett Expands Revolving Credit Facility To $120 Million 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 3U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 4U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 5U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 6U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 7
Cached News: